ARCHIVES

Coulter And Venture Capital Firm Form Company To Develop B1 Antibody For NHL

This article is from The Cancer Letter archive.

Vol. 21 No. 17 | April 28, 1995

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995

Panel Resumes Deliberations

January 4, 1980

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

Acupuncture Eases Radiation-Induced Dry Mouth In Patients

April 24, 2009

In Brief: Carbone To Leave NCI for Wisconsin ACS’ Holleb Says Tobacco Industry Tries to Hide Ad Warning

October 3, 1975

Brandt Tells NIK There May Be No Exceptions To DRG Regulations, Maybe a Few At Comprehensive Centers

June 24, 1983